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Introduction
Familial Mediterranean Fever (FMF) is a disease that starts
in childhood and can lead to significant morbidity. In
2012, a European initiative called SHARE (Single Hub and
Access point for pediatric Rheumatology in Europe) has
been launched to optimize and disseminate diagnostic and
management regimens in Europe for children and young
adults with rheumatic diseases. For FMF, attention was
focused on genetics.
Objectives
The aim of the SHARE recommendations in FMF is to
provide a diagnostic tool for inexperienced pediatric rheu-
matologists to cope with FMF in their clinical practice.
This is possible through a correct interpretation of the
diagnostic value of MEFV gene mutations in predicting
FMF phenotype.
Methods
Evidence-based recommendations were developed using
the European League Against Rheumatism (EULAR)
standard operating procedure. An expert committee was
instituted, consisting of pediatric rheumatologists, and
search terms for the systematic literature review were
defined. Two independent experts scored articles for
validity and level of evidence. Recommendations derived
from the literature were evaluated by an online survey.
Those with less than 80% agreement during the online
survey were reformulated. Subsequently, all recommenda-
tions were discussed at a consensus meeting using the
nominal group technique. Recommendations were
accepted if more than 80% agreement was reached.
Results
The literature search yielded 3386 articles, of which 240
about genetics and, among them, 25 considered relevant
and therefore scored for validity and level of evidence. 17
articles were scored valid and used in the formulation of
the recommendations. 9 recommendations for diagnosis
were suggested in the online survey and 8 were finally
accepted with 100% agreement after the consensus
meeting. Topics covered for diagnosis were: clinical versus
genetic diagnosis of FMF; genotype – phenotype correla-
tion; genotype – age at onset correlation; silent carriers
and risk for amyloidosis; role of the specialist in FMF
diagnosis.
Conclusion
The SHARE initiative provides recommendations for the
diagnosis of FMF and thereby facilitates improvement
and uniformity of care throughout Europe.
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